The Protocol Review and Monitoring System (PRMS) oversees and ensures the scientific merit, appropriate resourcing and progress of all clinical studies at the University of Kansas Cancer Center (KUCC). The PRMS evaluation process occurs prior to submission to the University of Kansas Medical Center (KUMC) institutional review board (IRB), called the Human Subjects Committee (HSC). The PRMS process is complementary to the HSC review and does not overlap or duplicate the responsibilities of the HSC. The three components of the PRMS are the Disease Working Groups (DWGs;Parvesh Kumar, MD), the Executive Resourcing Committee (ERC;Raymond P. Perez, MD, Chair) and the Protocol Review and Monitoring Committee (PRMC;Stephen K. Williamson, MD, Chair). Although each component has a unique role, combined these are aligned to ensure that research ideas and protocols are efficiently moved through the system, receive high-quality peer-review and monitoring, and that the research portfolio is consistent with KUCC clinical research priorities. The DWGs are charged with initial review of protocol merit and feasibility, and with prioritizing by disease-site and stage. The ERC reviews protocol resource requirements, available funding, fit within the DWG portfolio, and alignment with KUCC research programs and priorities. The PRMC performs independent scientific merit and biostatistical reviews, including rationale, design, statistical analysis plan, and adequacy of the data safety monitoring. In 2010, a total of 89 new protocols were reviewed by the PRMS for merit, and 240 active protocols were monitored for scientific progress. The PRMC also monitors active protocols at least annually for continued scientific merit, clinical appropriateness, progress toward completion of scientific objectives, and accrual status, and terminates studies as appropriate. The PRMS is overseen by Deputy Director, Kapil N. Bhalla, MD and is administratively supported by the KUCC Clinical Trials Management shared resource.

Public Health Relevance

For KUCC cancer clinical research, the PRMS: * Prioritizes competing studies and resources based upon KUCC institutional prioritization plan. * Reviews all proposed cancer related protocols for merit of scientific rationale, accrual goals and ethical appropriateness. * Reviews the statistical analysis plan and appropriateness of trial design. * Reviews the adequacy of the data safety monitoring plan to assure oversight of patient safety * Monitors the accrual and scientific progress of studies

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA168524-03
Application #
8702117
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
3
Fiscal Year
2014
Total Cost
$12,782
Indirect Cost
Name
University of Kansas
Department
Type
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Jiang, Yu; Simon, Steve; Mayo, Matthew S et al. (2015) Modeling and validating Bayesian accrual models on clinical data and simulations using adaptive priors. Stat Med 34:613-29
Zeineldin, Maged; Jensen, Derek; Paranjape, Smita R et al. (2014) Human cancer xenografts in outbred nude mice can be confounded by polymorphisms in a modifier of tumorigenesis. Genetics 197:1365-76
Winham, Stacey J; Armasu, Sebastian M; Cicek, Mine S et al. (2014) Genome-wide investigation of regional blood-based DNA methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer. Genet Epidemiol 38:457-66
Block, Matthew S; Charbonneau, Bridget; Vierkant, Robert A et al. (2014) Variation in NF-?B signaling pathways and survival in invasive epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 23:1421-7
Pessetto, Ziyan Y; Ma, Yan; Hirst, Jeff J et al. (2014) Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor. Mol Cancer Ther 13:2276-87
Purrington, Kristen S; Slager, Susan; Eccles, Diana et al. (2014) Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis 35:1012-9
Bohl, Christopher R; Harihar, Sitaram; Denning, Warren L et al. (2014) Metastasis suppressors in breast cancers: mechanistic insights and clinical potential. J Mol Med (Berl) 92:13-30
Peterson, Kenneth R; Costa, Flávia C; Fedosyuk, Halyna et al. (2014) A cell-based high-throughput screen for novel chemical inducers of fetal hemoglobin for treatment of hemoglobinopathies. PLoS One 9:e107006
Meneely, Kathleen M; Luo, Qianyi; Riley, Andrew P et al. (2014) Expanding the results of a high throughput screen against an isochorismate-pyruvate lyase to enzymes of a similar scaffold or mechanism. Bioorg Med Chem 22:5961-9
Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline et al. (2014) DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10:e1004256

Showing the most recent 10 out of 26 publications